ML-185
ML-185 is a small molecule inhibitor that has been studied for its potential therapeutic effects in various disease models. It is primarily known for its role in modulating specific biochemical pathways that are implicated in cancer and neurodegenerative diseases.
Mechanism of Action[edit | edit source]
ML-185 functions by inhibiting a specific enzyme or receptor that is overactive in certain pathological conditions. The exact target of ML-185 is often a protein involved in the regulation of cell growth and survival, making it a candidate for anticancer therapy. By binding to this target, ML-185 can disrupt the signaling pathways that lead to uncontrolled cell proliferation.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of ML-185 includes its absorption, distribution, metabolism, and excretion (ADME) characteristics. Studies have shown that ML-185 is well-absorbed when administered orally, with a bioavailability that allows for effective systemic distribution. It is metabolized primarily in the liver, and its metabolites are excreted via the renal and biliary systems.
Clinical Applications[edit | edit source]
ML-185 has been investigated in preclinical models for its efficacy in treating various types of cancer, including breast cancer, lung cancer, and prostate cancer. Additionally, its potential neuroprotective effects are being explored in models of Alzheimer's disease and Parkinson's disease.
Research and Development[edit | edit source]
Ongoing research is focused on optimizing the chemical structure of ML-185 to enhance its potency and selectivity. Clinical trials are being designed to evaluate its safety and efficacy in human subjects. The development of ML-185 is part of a broader effort to create targeted therapies that minimize side effects compared to traditional chemotherapy.
Safety and Toxicity[edit | edit source]
Preclinical studies have assessed the safety profile of ML-185, indicating a favorable therapeutic index. However, potential side effects and toxicity need to be thoroughly evaluated in clinical trials to ensure its safety for human use.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
